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Abstract
Background: A devastating late injury caused by radiation is pulmonary fibrosis. This risk may limit the volume of
irradiation and compromise potentially curative therapy. Therefore, development of a therapy to prevent this toxicity
can be of great benefit for this patient population. Activation of the chemokine receptor CXCR4 by its ligand stromal
cell-derived factor 1 (SDF-1/CXCL12) may be important in the development of radiation-induced pulmonary fibrosis.
Here, we tested whether MSX-122, a novel small molecule and partial CXCR4 antagonist, can block development of
this fibrotic process.
Methodology/Principal Findings: The radiation-induced lung fibrosis model used was C57BL/6 mice irradiated to
the entire thorax or right hemithorax to 20 Gy. Our parabiotic model involved joining a transgenic C57BL/6 mouse
expressing GFP with a wild-type mouse that was subsequently irradiated to assess for migration of GFP+ bone
marrow-derived progenitor cells to the irradiated lung. CXCL12 levels in the bronchoalveolar lavage fluid (BALF) and
serum after irradiation were determined by ELISA. CXCR4 and CXCL12 mRNA in the irradiated lung was determined
by RNase protection assay. Irradiated mice were treated daily with AMD3100, an established CXCR4 antagonist;
MSX-122; and their corresponding vehicles to determine impact of drug treatment on fibrosis development. Fibrosis
was assessed by serial CTs and histology. After irradiation, CXCL12 levels increased in BALF and serum with a
corresponding rise in CXCR4 mRNA within irradiated lungs consistent with recruitment of a CXCR4+ cell population.
Using our parabiotic model, we demonstrated recruitment of CXCR4+ bone marrow-derived mesenchymal stem
cells, identified based on marker expression, to irradiated lungs. Finally, irradiated mice that received MSX-122 had
significant reductions in development of pulmonary fibrosis while AMD3100 did not significantly suppress this fibrotic
process.
Conclusions/Significance: CXCR4 inhibition by drugs such as MSX-122 may alleviate potential radiation-induced
lung injury, presenting future therapeutic opportunities for patients requiring chest irradiation.
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Introduction
Cancer therapy may require radiation treatment in the chest,
potentially resulting in significant dose to lung tissue. These
patients are at risk for developing lung radiation injury including
pulmonary fibrosis (PF), an incurable, late radiation toxicity that
can cause significant morbidity and even mortality depending
on the volume of lung affected (For review, see [1]). After
radiation exposure, Type I pneumocytes are depleted with
accompanying Type II pneumocyte hyperplasia as part of the
process of alveolar epithelial regeneration. During this process,
local cytokine/chemokine production leads to recruitment and
retention of inflammatory cells including macrophages. As
acute inflammation resolves, fibroblasts are recruited, resulting
in interstitial collagen deposition and alveolar septal thickening.
Recruitment of fibroblasts is critical in the development of
idiopathic PF (For review, see [2]). It is now known that bone
marrow (BM)-derived fibroblast progenitor cells, known as
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fibrocytes, are recruited and likely play a major role in the
fibrotic process [3]. Similarly, after bleomycin-induced injury,
BM-derived fibrocytes, which express CXCR4, are recruited to
fibrogenic regions of lung [4,5]. Neutralizing antibody against
CXCL12 can prevent the recruitment of circulating fibrocytes to
bleomycin-damaged lung and suppress the development of
fibrosis [4]. Further characterization of these BM-derived cells
demonstrate expression of the mesenchymal stem cell markers
CD44 and CD105 in addition to CXCR4 but lack of the
hematopoetic stem cell marker CD45 [5]. Therefore, the
CXCR4/CXCL12-axis appears critical in recruiting BM-derived
precursors that differentiate into the fibroblasts that cause PF.
To date, several CXCR4 antagonists have been developed
(For review, see [6]). TN14003, a 14-mer peptide, blocks
development of PF in bleomycin-treated C57BL/6 mice [5].
AMD3100 (Plerixafor), an FDA-approved small molecule
CXCR4 antagonist, has also been tested on bleomycin-treated
mice. While AMD3100 is effective at blocking stem cell homing,
it also increases stem cell mobilization, which has led to its use
for increasing stem cell yields in preparation for
autotransplantation. Consistent with its ability to block homing,
Watanabe et al. found that initiating the drug prior to bleomycin
exposure decreased development of PF and improved mouse
survival [7]. However, if AMD3100 was initiated after bleomycin
exposure, fibrosis actually increased possibly due, in part, to
mobilization of stem cells from the bone marrow.
While bleomycin- and radiation-induced PF has widely
disparate latencies in mouse models ranging from 2-8 weeks
(for bleomycin) to upwards of 6 months or more (for radiation)
[8,9], they have similar mechanisms of action, namely
production of DNA strand breaks. In addition, a genetic factor
thought to predict susceptibility to bleomycin-induced PF
similarly predicts radiation-induced PF [8].
In this study, we sought to characterize the CXCR4/CXCL12-
axis in a mouse model of radiation-induced PF and assess the
effect of blocking CXCR4 on the pathogenesis of this late
toxicity. We recently reported the development of a unique
partial anti-CXCR4 compound, MSX-122, that blocks homing of
metastatic and inflammatory cells without mobilizing stem cells
[10]. This drug can intervene in the Gαi-signaling pathway
(cAMP modulation), but not the Gq-pathway (calcium flux).
More details about differences between this partial anti-CXCR4
compound and previous inhibitors has been reported [10].
Here, we assessed the effectiveness of MSX-122 and
AMD3100 at inhibiting radiation-induced PF.
Materials and Methods
Species used and handling of animals
Female C57BL/6 mice were used for all experiments. All
animals were housed in the Emory animal facility. Protocols for
animal studies were reviewed and approved by the Institutional
Animal Care and Use Committee at Emory University (IACUC
protocol numbers:170-2008 and 065-2006). Emory DAR
(Division of Animal Resources) has experienced clinical
veterinary and animal caretaker support staff who are well-
trained in the care of rodents. All animals were monitored daily
by the investigators and/or by members of the clinical
veterinary staff concerning general health and to detect signs
of discomfort. Any animal showing signs of discomfort, pain or
distress was sacrificed immediately following IACUC guideline
for endpoints. All reasonable measures were taken to ensure
the health and well being of the animals during the course of
the study. The procedures to be used for animal care were
consistent with those established by the NIH and the vivarium
was fully accredited by the AAALAC. All experimental results
adhere to the ARRIVE guidelines for the reporting of animal
research [11].
Thoracic irradiation models
All irradiation was performed on a clinical linear accelerator.
For right hemithoracic irradiation, three 8-week old female
C57BL/6 mice were anesthetized and thoracic regions
corresponding to right lungs were aligned. 1.0 cm thickness
water-density flexible bolus pieces were placed on top of the
mice for dose buildup and collimated fields that encompassed
the right hemithorax were used (Figure 1A). For whole thoracic
irradiation, 6 mice were simultaneously treated. 6 MV photons
were used to deliver 20 Gy prescribed at Dmax (1.0 cm bolus +
~0.5 cm chest). All animal experiments were approved by the
IACUC at Emory University.
CT image analysis
For initial testing, computed tomography (CT) scans were
obtained on a Lightspeed RT-16 unit (GE Healthcare) with the
following parameters: 120-kV, 100-mA, 9.6-cm FOV, 0.625-mm
slice thickness over 3.5-cm scan region (entire lung). A 20
week post-irradiation CT scan was done for all drug- or vehicle-
treated groups. CT images were then transferred to the
VelocityAI software (Velocity Medical Systems), and a three-
dimensional contour of the irradiated lung was determined
(Figure 1B). Plots of Hounsfield-units (HU) versus percentage
of the irradiated lung volume (% volume) were generated. %
volume > -200 HU was utilized as a marker for the extent of
fibrosis. Also, CT- and histology-based assessments were
normalized to percent-scale to evaluate the efficacy of the
CXCR4 antagonists in attenuating radiation-induced PF.
Parabiotic model and flow cytometry analysis
A transgenic C57BL/6 mouse expressing GFP under the
control of the β-actin promoter was surgically joined to a wild-
type mouse to allow sharing of blood circulation (Figure 2A) as
previously reported [12]. Mice were housed together > two
weeks before surgery to increase compatibility. Once
anesthetized, elongated diamond-shaped skin pieces (long-
axis extending from shoulder to hip, 1.0 cm short-axis width)
were removed from opposite sides of each mouse. Exterior
shoulder and hip muscles were sutured together with 4-0
prolene sutures and skin was joined with a continuous 3-0
prolene suture. GFP+ (left) and wild-type (right) mice make up
the parabiotic pair. Cross-circulation is usually established by
day 3 and completed by day 7. Once established (at least 2-4
weeks post-parabiosis), right hemithoracic irradiation is
performed on the wild-type half of the parabiont (Figure 3A).
Irradiated lungs are harvested at various time-points for flow
cytometry analysis to confirm presence of recruited BM-derived
CXCR4 Blockade to Prevent Radiation Lung Injury
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Figure 1.  Quantification of PF in a hemithoracic irradiation model.  A, Representative portal image of three mice receiving right
hemithoracic radiation (region of treatment in pink) is shown. B, VelocityAI interface was used to show representative axial/coronal/
sagittal slices of reconstructed CT image set with the right lung as 3D-volume of interest contoured (red). C-E, Representative H&E-
stained lung slides (C), corresponding axial CT images (D) and plots of HU versus %volume (E) at C (untreated), 8(1), 12(2), 16(3),
and 20(4) weeks after irradiation are shown.
doi: 10.1371/journal.pone.0079768.g001
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cells as previously described [5]. As a control, the wild-type half
of parabiont was subjected to bleomycin-induced lung injury [5]
and sacrificed at day-21. Lungs were again harvested for flow
cytometry analysis.
BALF and serum CXCL12 protein concentration
Mouse bronchoalveolar lavage fluid (BALF) and serum
CXCL12 concentrations were measured at 0, 1, 3, 7, 14, and
28 days after whole thoracic irradiation. To obtain BALF, mice
tracheae were cannulated with 20-guage needles, and lungs
were instilled with 0.6-mL of PBS and recovered twice. The
BALF was pooled and cells/debris spun down. Blood was
obtained by heart puncture in sacrificed mice and cellular
components were removed by centrifugation. The
concentration of CXCL12 in the BALF and serum was
determined by ELISA, according to manufacturer’s
recommendations (R&D Systems). Results were graphed as
absolute concentrations based on a standard curve developed
for each experiment (Figure 4A-B).
CXCR4/CXCL12 mRNA quantitation
Lung CXCR4 and CXCL12 mRNA levels were determined at
the same time-points. Flash frozen lung samples were used for
extraction of total RNA with Trizol (Invitrogen). mRNA
quantitation was determined by RNase protection assay as
previously described [13] except that the probes used for
Figure 2.  Migration of BMDMSCs to the bleomycin-injured lungs.  A, Parabiont consisting of GFP-positive (GFP+) and wild-
type (GFP-) mouse is shown. B, Flow cytometry analysis of leukocytes from the three sets of pooled blood of three parabionts
(experiment using 9 parabiont pairs) showing roughly half of the cells show green fluorescence consistent with GFP positivity. C,
Flow cytometry analysis of 200,000 cells prepared from three lungs of bleomycin- (black) or saline-treated (white) parabionts at
day-21 are shown. Graphs compare percent of total cells that is GFP+(left) and percent of GFP+cells that is CD45-/CD44+/CD105+
(right). Error bars represent standard error of the mean (SEM).
doi: 10.1371/journal.pone.0079768.g002
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detection of CXCL12 and CXCR4 span 369 nucleotides (base
39-407 of mRNA) and 263 nucleotides (base 447-709 of
mRNA), respectively. Protection of actin mRNA (Ambion) was
used as the normalization control. Protected RNAs were
detected by phosphor imaging on Typhoon 9210 using
ImageQuant software from Molecular Dynamics (GE
Healthcare). Results are graphed as relative levels with the day
0 values arbitrarily set at one based on a standard curve
developed for each experiment (Figure 4A-B).
Histology
At 20-weeks post-irradiation, all lungs were collected and
fixed with 4% paraformaldehyde for 24 hours, paraffin-
embedded and sectioned at 6-μm. Slides were then shipped to
the University of Pittsburgh where they were stained with
hematoxylin and eosin (H&E) and Masson’s trichrome. A blind
quantification was carried out in which the severity of the
fibrosis (cell numbers and strength of staining) is quantified
from 0 (normal) to IV severe (no airspace), II and III are
intermediate. We selected 3 slides of lungs (middle, 50-µm
above and below from the middle) per animal. Therefore the
maximum PF score per animal is 12-point (100% in Figure 5A).
In addition to the 20 week-irradiated groups, mice in the
different groups were sacrificed at earlier time points (at 0, 8,
12, and 16 post-irradiation, n=6 per group) for histology-based
assessment of PF.
Administration of CXCR4 antagonists
Irradiated mice were subject to treatment with the CXCR4
antagonists AMD3100 and MSX-122 (n=10 each). Daily
subcutaneous injections (s.c.) of 10 mg/kg AMD3100 in 100-μL
vehicle (PBS) or intraperitoneal injections (i.p.) of 10 mg/kg
MSX-122 in 100-μL vehicle (dissolved in 10% DMSO and 90%
of 45% 2-hydroxypropyl-β-cyclodextrin (CD) (Fluka) in PBS)
were given over 20 weeks (initiated 24 hours before
irradiation). To assess the treatment outcome, AMD3100-
treated mice were compared with subcutaneous PBS and
MSX-122-treated mice were compared with i.p. 10%
DMSO/45% CD vehicle controls.
Figure 3.  Use of parabiosis in hemithoracic irradiation animal model.  A, Representative portal image of three parabionts
receiving right hemithoracic radiation (region of treatment in pink) is shown. B, Graph (n=3) compares percent of GFP+/CD45-cells
in the lungs at 0, 2, 4, 8, and 12-weeks post-irradiation. Error bars represent SEM. * indicates statistically significant difference
(p<0.05) compared with value at 0 weeks.
doi: 10.1371/journal.pone.0079768.g003
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Statistical Methods
For comparison between groups, unpaired, two-tailed
student’s t-test was used.
Results
CT-based fibrosis assessment correlates to histology
in hemithoracic radiation-induced PF model
Whole-thoracic irradiation to mice results in significant
morbidity and mortality. Therefore, we established a
hemithoracic irradiation model that yielded less than 5%
radiation-induced mortality (20 Gy, single dose) up to 20 weeks
post-irradiation. CT scans were obtained on irradiated mice
and the region of interest (whole lung) was contoured on each
CT slice to define 3D-volumes of interest (Figure 1B). The
irradiated lungs of representative mice at the 0, 8, 12, 16, and
20 week time points were compared histologically and by CT
scan. H&E sections revealed pathologic changes such as
decreased alveolar spaces, thickened alveolar walls and
increased inflammatory cells and fibroblasts, clearly indicating
the radiation-induced lung injury and fibrosis over period of the
time (Figure 1C). The pathologic progression over time
correlated well with representative axial CT (Figure 1D),
suggesting the increase in the degree of radiation-induced lung
injury by plotting Hounsfield Units (HU) versus % volume of the
irradiated lung (Figure 1E).
Based on preliminary data, an arbitrary HU of -200 was set
as the threshold value for the presence of significant lung
hardening (% volume at -200 HU means the percent of the lung
whose tissue density is ≥ -200 HU, V-200). For the unirradiated
lung, normal alveolar structure is seen and median HU (HU50)
is ~ -500 while V-200 is < 5% (Fig. 1C-E.1). For the 12 week-
irradiated lung, HU50 shifts to the right and V-200 remains < 10%
(Fig. 1E.2); histologic evaluation of the same lung showed
patched areas of interstitial widening due to infiltration of
Figure 4.  CXCL12 and CXCR4 expression in lungs of mice after 20 Gy radiation.  Graphs of CXCL12 levels (ng/ml) (n=5 or 6)
measured by ELISA in (A) serum and (B) BALF as well as (C) CXCL12 and (D) CXCR4 normalized mRNA levels (n=5) measured
by RNase protection assay in lungs at 0, 1, 3, 7, 14 and 28-days post-irradiation (whole thorax) are shown. Error bars represent
SEM. * indicates statistically significant difference (p<0.05) compared with value at day-0.
doi: 10.1371/journal.pone.0079768.g004
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inflammatory cells and interstitial fibrosis (Fig. 1C.2 and data
not shown). At 16 weeks, the H&E staining of the lung exhibits
an increased interstitial thickening in association with
hyperplasia of alveolar lining cells, loss of normal alveoli and
dilatation of alveolar ducts and remaining alveoli with HU50 ~
-200 and V-200 ~ 50% (Fig. 1C-E.3). Finally, by 20 weeks, the
entire irradiated lung has opacified on CT scan, consistent with
finding of a solid lung in association with extensive infiltration of
inflammatory cells and interstitial fibrosis (Fig. 1C-E.4).
Parabiont model demonstrates recruitment of
mesenchymal stem cells
Bleomycin-treated parabiont.  The origins of fibrosis-
causing fibrocytes in idiopathic PF (lungs versus other sources)
have been debated. Xu et al. showed in a bleomycin-induced
PF mouse model that BM-derived CXCR4+ stem cells are
recruited to the exposed lung due to CXCL12 expression in
response to bleomycin [5]. We hypothesized that circulating
CXCR4+ BM-derived mesenchymal stem cells (BMDMSCs)
are recruited to irradiated-lungs and that this process is critical
for ultimate development of PF. To provide stronger evidence
Figure 5.  CXCR4 antagonists inhibit radiation-induced PF.  Mice underwent hemithoracic irradiation (20-Gy) and treated with
CXCR4 antagonists or their corresponding vehicle controls (n=10/group). A, Lungs were evaluated histologically after trichrome
staining (dark bars) or by CT scan (light bars) at 20-weeks post-irradiation. Histologic evaluation was scored (0-12) in each lung as
described in the Methods section. CT scan evaluation was scored as the percent volume of lung with density>-200 HU. In all
assessments, the vehicle controls values were normalized to 100% with drug-treated values expressed relative to corresponding
controls to evaluate the efficacy of the CXCR4 antagonists in attenuating radiation-induced PF. Error bar represents SEM. *
indicates statistically significant difference (p<0.05) compared with vehicle controls. B, Representative micrographs of trichrome
staining are shown in 4X and 40X magnification.
doi: 10.1371/journal.pone.0079768.g005
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for this idea, we adapted a parabiotic model where
regenerating tissues in an injured animal could be exposed to
marked circulating cells of a non-injured animal. This is
accomplished by forcing development of vascular anastomoses
between two syngeneic animals resulting in a single, shared
circulatory system. Parabiont consisting of GFP-expressing
transgenic mouse on the left and wild-type mouse on the right
is shown (Figure 2A). Flow analysis of leukocytes from the
blood of this parabiont indicates that approximately half are
GFP+ (Figure 2B). In this model, at day 21 after treatment of
the wild-type half with bleomycin, a significant increase in the
proportion of GFP+ cells in the lungs is seen compared with
untreated controls (Figure 2C, left). We next sought to
determine what percent of the detected GFP+ cells are
mesenchymal stem cells. Surface proteins including CD44 and
CD105 are generally expressed in BMDMSCs while CD45, a
hematopoetic marker, is generally not expressed in these cells.
The percent of GFP+ cells that are CD45-/CD44+/CD105+ in
the bleomycin-treated lungs is significantly increased compared
with untreated lungs (Figure 2C, right). This experiment
provides further evidence that bleomycin-induced lung injury
results in the accumulation of CXCR4+ mesenchymal stem
cells in the lung that are likely to be BMDMSCs although the
contribution of other cellular compartments that may serve as a
source of these cells can not be ruled out.
Radiation-treated parabiont.  To assess whether non-
hematopoietic BM stem cells, rather than regional cells, are
similarly recruited to the irradiated-lung, the right hemithorax of
the parabiotic wild-type half was irradiated (Figure 3A) and the
irradiated lung was collected. Because only the right lung was
collected per parabiont, there was insufficient yield of cells to
perform triple staining for CD45/CD44/CD105. We therefore
assessed for GFP+ cells that lacked expression of CD45 in the
irradiated lung. Quantitation of GFP+/CD45- cells shows a
trend of increasing recruitment of circulating stem cells that are
of non-hematopoietic lineage out to 8-weeks post-irradiation
(Figure 3B).
Lung irradiation increases activity of the CXCR4/
CXCL12-axis
We sought to determine whether the CXCR4/CXCL12-axis
responds to lung irradiation by measuring the serum and BAL
CXCL12 concentration, and CXCR4 and CXCL12 mRNA level
in the lungs at 0, 1, 3, 7, 14, and 28 days post-whole thoracic
irradiation. Both serum and BAL CXCL12 concentrations
showed fluctuating but increasing trends over the 28-day
course. In particular, BAL CXCL12 concentrations remained at
consistently and significantly higher levels out to day-28
compared with the day-0 level (Figure 4A-B). Lung CXCR4 and
CXCL12 mRNA levels also fluctuated but showed a general
trend of increase with the peak at day-28 post-irradiation
(Figure 4C-D).
MSX-122 attenuates radiation-induced PF
To test the impact of CXCR4 blockade with either AMD3100
or MSX-122 on development of radiation-induced PF, we
administered AMD3100, 10 mg/kg, s.c. or MSX-122, 10 mg/kg
i.p. for 20-weeks. We found from our initial pilot experiment that
a single 20-Gy dose to the lung at the 20-week time-point
resulted in fully 90% of untreated mice developing PF
confirmed by both trichrome staining-positivity (maximum score
12) and CT scan showing a significant volume with density >
-200 HU. Of note, AMD3100 was administered subcutaneously
because of significant mortality with intravenous or
intraperitoneal administration. Both histology-based and CT-
based assessments show that MSX-122 significantly
attenuated the development of fibrosis by 70%, while
AMD3100 only trended towards reduction in fibrosis (Figure
5A). Representative micrographs of trichrome-staining in each
group at low and high power are shown, with obvious blue
staining in the vehicle only group indicating significant
deposition of collagen (Figure 5B). The AMD3100-treated
group showed 50% mortality during the 20-weeks of treatment,
while no mortality was observed in the MSX-122- or vehicle-
treated (irradiated) groups.
Discussion
Development of a therapy to prevent the development of PF
could be of great benefit for at-risk patient populations.
Because CXCR4/CXCL12 interaction is important for
development of bleomycin-induced PF through recruitment of
BM-derived progenitor cells [4,5,7], we investigated whether it
is also critically involved in radiation-induced PF and whether
blocking CXCR4 with our novel compound, MSX-122, can
alleviate this process.
In our assessment, volumetric CT image analysis correlated
well with histological outcome. Our quantitative CT-based
assessment of PF is novel because it involves whole-lung
assessment, while typical histology analysis and scoring are
limited to a few selective sections per lung. Previous efforts at
characterizing PF with CT were similarly limited to the scoring
of selective regions [14,15]. In the future, this methodology may
serve as a non-invasive drug discovery tool for monitoring PF
or relevant lung injury development in mice.
Blocking CXCR4 using an antagonist such as TN14003 or
AMD3100 has been shown to effectively alleviate bleomycin-
induced PF [5,7]. We found that MSX-122 is similarly effective
[10,16]. Our current investigations also show that MSX-122 can
alleviate radiation-induced PF. However, AMD3100 did not
block this process to a significant extent in our system (Figure
5).
MSX-122 was discovered as one of the most potent CXCR4
inhibitors with reasonable bioavailability and has been carried
forward as a clinical drug candidate. It displays high affinity
binding to CXCR4 and inhibition of receptor function in the sub-
nM range without metal-chelating capability [10]. The current
clinical lead compound for CXCR4 inhibition, AMD3100, is a
metal-chelating bicyclam and this chelating ability is believed to
contribute to cardiotoxicity reported for this drug [17]. Metal-
chelation may also account for increased mortality (50% @20-
weeks) observed in mice treated with AMD3100. No such
increased mortality was noted in mice treated with MSX-122 or
the vehicle control groups. AMD3100 can also mobilize BM
stem cells and was recently approved by the FDA for this
purpose in patients undergoing harvesting of hematopoietic
CXCR4 Blockade to Prevent Radiation Lung Injury
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stem cells, which lacks in MSX-122. We speculate that this
factor may contribute to increased effectiveness of MSX-122
compared with AMD3100 for blocking radiation-induced PF.
While AMD3100 can decrease recruitment of CXCR4+
BMDMSCs to injured lung, it may also contribute to PF by
increasing the availability of BMDMSCs in the peripheral
circulation [18]. Therefore, while limited single use of AMD3100
is widely accepted, drugs with improved toxicity profiles may be
required for long-term clinical use.
Our results suggest that the CXCR4/CXCL12-axis is critical
in the development of radiation-induced PF in a mouse model
and that CXCR4 inhibition may alleviate potential radiation-
induced lung injury. Examining possible use of MSX-122 for
blocking PF among patients undergoing thoracic irradiation
warrants further investigations.
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